A Multi‐Center Double‐Blind Pilot Comparison of OnabotulinumtoxinA and Topiramate for the Prophylactic Treatment of Chronic Migraine

(Headache 2011;51:21‐32)

[1]  S. Silberstein,et al.  Topiramate in Migraine Prevention: Results of a Large Controlled Trial , 2004 .

[2]  P. Martelletti,et al.  Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience , 2006, The Journal of Headache and Pain.

[3]  Jes Olesen,et al.  The International Classification of Headache Disorders: 2nd edition. , 2004, Cephalalgia : an international journal of headache.

[4]  H. Diener,et al.  Evaluation of Carisbamate for the Treatment of Migraine in a Randomized, Double‐Blind Trial , 2009, Headache.

[5]  R. Lipton,et al.  Migraine prevalence, disease burden, and the need for preventive therapy , 2007, Neurology.

[6]  G. Zlotnik.  Re: “Botulinum Toxin Type A as a Migraine Preventive Treatment” (Silberstein S, Mathew N, Saper J, Jenkins S, for the BOTOX® Migraine Clinical Research Group. Headache. 2000;40:445‐450) , 2001, Headache.

[7]  R. Cady,et al.  Botulinum Toxin Type A as Migraine Preventive Treatment in Patients Previously Failing Oral Prophylactic Treatment Due To Compliance Issues , 2008, Headache.

[8]  J. Olesen,et al.  New Appendix Criteria Open for a Broader Concept of Chronic Migraine , 2006, Cephalalgia : an international journal of headache.

[9]  J. Olesen.  The International Classification of Headache Disorders , 2008, Headache.

[10]  H. Diener,et al.  OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial , 2010, Cephalalgia : an international journal of headache.

[11]  Giuseppe Orefice,et al.  Flunarizine in Prophylaxis of Childhood Migraine: A Double-Blind, Placebo-Controlled, Crossover Study , 1988, Cephalalgia : an international journal of headache.

[12]  M. Brin,et al.  Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study , 2000, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[13]  S. Aurora,et al.  Botulinum Toxin Type A Prophylactic Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Exploratory Study , 2006, Headache.

[14]  M. Farré,et al.  Placebo response in the prophylaxis of migraine: A meta‐analysis , 2008, European journal of pain.

[15]  Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. , 1988, Cephalalgia : an international journal of headache.

[16]  J. Gracies,et al.  Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologySYMBOL , 2008, Neurology.

[17]  Peter J. Goadsby,et al.  A Report on the Journal 2004 , 2004 .

[18]  N. Mathew,et al.  A Double‐Blind Comparison of OnabotulinumtoxinA (BOTOX®) and Topiramate (TOPAMAX®) for the Prophylactic Treatment of Chronic Migraine: A Pilot Study , 2009, Headache.

[19]  T. Steiner,et al.  Lamotrigine versus Placebo in the Prophylaxis of Migraine with and Without aura , 1997, Cephalalgia : an international journal of headache.

[20]  S. Silberstein,et al.  Botulinum Toxin Type A as a Migraine Preventive Treatment , 2000 .

[21]  P. M. van der Kuy,et al.  A Quantification of the Placebo Response in Migraine Prophylaxis , 2002, Cephalalgia : an international journal of headache.

[22]  T. Einarson,et al.  Efficacy of Botulinum Toxin Type A for the Prophylaxis of Episodic Migraine Headaches: A Meta‐analysis of Randomized, Double‐Blind, Placebo‐Controlled Trials , 2009, Pharmacotherapy.